Author Information
Thomas Verstraeten is affiliated with P95 Pharmacovigilance and Epidemiology Services, located in Leuven, Belgium. His work primarily involves the fields of pharmacovigilance and epidemiology, contributing significantly to understanding infectious diseases and vaccine efficacy.Research Contributions
In 2021, Thomas Verstraeten published several important papers covering various aspects of infectious diseases and their management. Notable works include studies on the decrease in norovirus infections in Germany following COVID-19 containment measures, the burden of norovirus disease in children across multiple countries, and the estimation of death risk attributable to acute gastroenteritis in hospitalized adults in England. He has also contributed to research on the real-world impact and effectiveness of the quadrivalent HPV vaccine, the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2, and the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. Additionally, Verstraeten has been involved in epidemiological cohort studies of SARS-CoV-2 and COVID-19 in German healthcare workers, model estimates of hospitalization discharge rates for norovirus gastroenteritis in Europe, and economic evaluations of universal varicella vaccination in Mexico.Aliases
The author is known by several aliases including T Verstraeten, T. Verstraeten, Tom Verstraeten, and Thomas Verstraeten. The most appropriate name to refer to him is Thomas Verstraeten.Publication and Citation Metrics
| Metric |
Value |
| Citation Count |
3690 |
| H-Index |
32 |
| Paper Count |
114 |
